All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
More information on our cookie policy.
BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Special reports
Artificial intelligence
Coronavirus
Diagnosing and tracking COVID-19
Drugs to Watch 2020
The next pandemic
Premium reports
BioWorld Financings Reports
Disease Forecast Reports
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Sunday, April 11, 2021
Home
» Phase II study evaluates E-52862 in early treatment of outpatients with mild COVID-19 symptoms
Phase II study evaluates E-52862 in early treatment of outpatients with mild COVID-19 symptoms
Feb. 15, 2021
No Comments
Article reprints
Source:
https://science.bioworld.com/ddn/article.do?id=176463
BioWorld Science
Related Articles
FDA clears IND for phase II study of CYTO-205 as treatment of mild COVID-19
